New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

BACKGROUND: The monoclonal antibody natalizumab (NAT) inhibits the migration of lymphocytes throughout the blood–brain barrier by blocking very late antigen (VLA)-4 interactions, thereby reducing inflammatory central nervous system (CNS) activity in patients with multiple sclerosis (MS). We evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehr, T., Proschmann, U., Thomas, K., Marggraf, M., Straube, E., Reichmann, H., Chan, A., Ziemssen, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924246/
https://www.ncbi.nlm.nih.gov/pubmed/27349895
http://dx.doi.org/10.1186/s12974-016-0635-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924246/
https://www.ncbi.nlm.nih.gov/pubmed/27349895
http://dx.doi.org/10.1186/s12974-016-0635-2

Ejemplares similares